Richter Gedeon Vegyeszeti Gyar Rt

Stichting Rega Vzw

Miklos Low

Miklos Nagy

Laszlo Szporny

Masanori Baba

Sandor Gorog

Lajos Kisfaludy

Erik D De Clercq

Sandorne Gyorgyi

Egon Karpati

Sandor Bajusz

Katalin Csomor

Istvan Horvath

Istvan Schon

Lajos Kovacs

Attila Juhasz

Tamas Szirtes

Botond Penke

Lajos Balaspiri

Laszlo Varga

Gyorgy Dobo

Vince Varro

Geza Ivanyi

Laszlo Graf

Kalman Medzihradszky

Raymund Machovich

Rosa Beks

Maria Sz Sarkozi

Andrae Turan

Kalman Kovacs

Peter Pallai

Janos Lonovics

Judit Low, Nee Kaloczy

Judit Gyorgyi Nee Edelenyi

Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.

Sulphated vinyl polymer in composition for treating retroviral infections

Sulphated vinyl polymers in compositions for treating retroviral

The invention relates to new, pharmaceutically active copolymers with heparin-like activity, pharmaceutically acceptable salts thereof and a process for their preparation. The new copolymers comprise the units of the formula I ##STR1## wherein X stands for hydrogen or methyl and Y is hydrogen, units of the formula III ##STR2## optionally units of the formula II ##STR3## wherein Z' is hydrogen, and chain terminating units, formed from the units of the formulae I, III and optionally II under the conditions of copolymerization, in a statistical arrangement, and the pharmaceutically acceptable salts thereof, which contain, in addition to the above chain-members, units of the formulae IV and/or V ##STR4## wherein A is a cation/ satisfactorily replace the organogenic heparin, or give a synergistic combination with that,

Pharmaceutically active copolymers, process for their preparation and

A process for the preparation of L-aspartyl-(O-sulfato-L-tyrosyl)-L-methionyl-glycyl-L-tryptophyl-L-methion yl-L-aspartyl-L-phenylalanine amide, which comprises treating the protected octapeptide amide of the general formula (II) ##STR1## wherein X is BOC, Cbz or Ddz,

Process for the preparation of the cholecystokinin-pancreozymin

The invention relates to the preparation of biologically active polypeptides containing the aspartyl group, particularly an aspartyl-glycine moiety, using the active-ester technique. According to the method of the invention, human adrenocorticotropic hormone and its fragments characteristic to the individual species, as well as the blocked derivatives of such compounds are prepared by the pentafluorophenol method, i.e., the carboxy group of the acylating component is activated by converting it into pentafluorophenyl ester in the coupling reaction carried out with blocked peptides containing the aspartyl group or an aspartylglycine moiety. The acylation is carried out preferably using equimolar quantities of the respective reactants. The free peptides obtained after removing the blocking groups can be converted into their acid addition salts or pharmaceutically acceptable complexes or condensates. Human adrenocorticotropic hormone and its derivatives are valuable substances of therapeutical activity.

Process for the preparation of biologically active polypeptides

Growing community of inventors

Budapest, Hungary

Miklos Low